Cyclic Kinase Inhibitor Discovery
Oncodesign has utilized a novel approach for identifying highly selective kinase inhibitors by synthesizing macrocyclic molecules (containing large cycles) with a low molecular weight, says Jan Hoflack, Ph.D., CSO.
Dr. Hoflack explains that this Nanocyclix® platform has generated high selectivity across the kinome because the cyclical nature of each inhibitor provides for the utmost degree of three-dimensional shape complementarity with their kinase target. Similar to a type 1 inhibitor, the macrocyclic molecule binds to the kinase’s ATP binding site, but with three major determinants: a strong hinge region interaction, an interaction close to the gatekeeper residue, and an interaction in the ribose pocket.
“These are truly differentiated compounds, as they allow us to block kinases for which currently no inhibitors exist. They take us into novel chemical space, and as such create first-in-class opportunities against unexplored kinases. No other noncyclic molecule can do this type of binding: the cycle forces our macrocyclic inhibitors into a particular conformation, and there is high selectivity because the binding is based purely on shape,” Dr. Hoflack comments.
The macrocylic nature of Oncodesign’s molecules creates a three-dimensional shape that perfectly fits with the kinase, according to Dr. Hoflack. This leads to a selectivity among kinases that would normally be obtained in a linear molecule by adding longer chains, thus increasing the size of the molecule in order to reach the required selectivity. Because of this, these macrocylic inhibitors are about half the size of conventional kinase inhibitors: they typically have a molecular weight around 300.
“Any molecule with a molecular weight more than 400 will have difficulty in getting through the blood-brain barrier if targeting the CNS, and for any application, a molecular weight above 500 is expected to lead to problems related to optimizing the ADME and PK properties,” according to Dr. Hoflack. “Oncodesign offers a new technology, where we obtain high selectivity and potency but still use small molecules.”
Dr. Hoflack indicated that Oncodesign’s diverse collection of over 50 kinase scaffolds and 300 linkers comprising a total of 5,000 compounds in the macrocyclic platform is very different from a high-throughput screening collection. These 5,000 inhibitor compounds have already displayed strong potencies in the low nanomolar range against the kinome, including both previously characterized kinases and kinases that have been unexplored by the pharmaceutical industry.
Once an initial ATP scaffold/linker combination with a good fit has been identified, the compounds are further optimized by modifying the length and functionality of the cyclic linker. Preferred inhibitors typically bind to 1–4 kinases on average, but Dr. Hoflack and colleagues have been driving the specificity further, as well as improving solubility of the compounds.
The Nanocyclix platform has been utilized in various therapeutic areas, especially for unexplored kinases. Cell-based phosphorylation assays have shown promise for macrocyclic inhibitors of RIP2, which is a target for autoinflammatory diseases like asthma, IBD, and rheumatoid arthritis, and LRRK2, a key kinase active in the brain in Parkinson’s disease.
These and other inhibitors are currently being examined in vivo. Oncodesign has also been examining how to improve the safety of conventional kinase inhibitors in pancreatic and ovarian cancer cell lines, specifically by preventing resistance to targeted treatments by applying the Nanocyclix platform.
Leyi Gong, Ph.D., program director of medicinal chemistry at SRI Biosciences (a division of SRI International), investigated a class of bicyclic molecules called quinolones, while previously working at Roche. Dr. Gong and her colleagues at Roche were interested in JNK inhibition for a number of disease indications.
They implemented three different approaches in their study to identify inhibitors of JNK: a high-throughput screening approach, using a few million of Roche’s compounds, a focused screening approach, where they collected in-house kinase inhibitors and inhibitors from the literature into a focused library for screening, and an approach just using literature-published leads. This resulted in the discovery of a novel series of kinase inhibitors, 4-quinolones. These compounds are highly selective because they were first identified as solely targeting JNK-1,-2, and -3.
Dr. Gong and colleagues modeled the predicted binding mode of this inhibitor series and later obtained the inhibitor-bound JNK x-ray crystallography, and they noticed that this unique binding mode was shared with another series published by Takeda Pharmaceutical. By combining their hits from high-throughput screening with Takeda’s hits, this led to the researchers engineering a new series of quinolones.
The cyclic structure of this quinolone series accounts for this intrinsic JNK selectivity by accessing a unique binding pocket, which prevents the inhibitor from binding to any other kinases. These type I inhibitors (with a representative molecular weight of 450) bind to the ATP pocket on JNK, but also bind to another unique binding pocket that does not exist on other kinases aside from JNK-1,-2, and -3.
The researchers used structure-based drug design to improve potency and various physical and chemical properties. At first, the series appeared to highly lipophilic, but structure-based drug design was implemented to generate lower lipophilicity while maintaining potency and increasing solubility. The potency was also improved by introducing a series of small lipophilic groups to allow the inhibitor to have better contact with JNK.
“In in vitro assays, there was really a clear distinction between binding to JNK or any other kinase,” Dr. Gong explains. “We profiled the quinolone compound against 317 different kinases and obtained a quantitative measurement for JNK inhibition: the compound had a Kd of 50–200 nm for JNK-1,-2, and -3 but greater than 10 uM for any other kinase in the test. Because of this selectivity, when we began in vivo work, we were confident that what we saw could be attributed only to the activity of our quinolone inhibitor.”
The in vivo model induced inflammation in the mouse lung to mimic an asthmatic response. To examine how one of the lead quinolone compounds reduced inflammation, Dr. Gong and her collaborators measured neutrophil levels in BAL (Brochoalveolar lavage) and AP-1 (transcription factor family phosphorylated by JNK) activity in the lung, and saw a reduction in both four hours after the inhibitor was administered at 10 mg/kg.
Dr. Gong pointed out that there are many opportunities for this work to progress, as a number of different JNK inhibitors in the literature besides quinolones present this unique binding mode that she and her colleagues have investigated.
“The quinolone structure has shown to be very important for JNK selectivity, and we have also identified other compounds that could have a similar effect due to their specific binding mode. Other cyclical chemical templates from AstraZeneca, Abbott Laboratories, and Takeda Pharmaceutical mimic the quinolone binding motif, in which they also occupy the unique JNK binding pocket not present in other kinases.”